Heron Therapeutics Inc
Open
BrancheGesundheitswesen
0.3 -3.23
Übersicht
Veränderung der Aktienkurses
24h
Min
0.3
Max
0.32
Einkommen | 2.6M -5.5M |
|---|---|
Verkäufe | 3M 38M |
EPS | -0.03 |
Gewinnspanne | -14.573 |
Angestellte | 128 |
EBITDA | 2.1M -5.5M |
Nächstes Ergebnis | 3. Nov. 2026 |
|---|
Marktkapitalisierung | -36M 61M |
|---|---|
Vorheriger Eröffnungskurs | 3.53 |
Vorheriger Schlusskurs | 0.3 |
Nachrichtenstimmung
By Acuity
11%
89%
18 / 340 Ranking in Healthcare
Heron Therapeutics Inc Chart
Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.
Ähnliche Nachrichten
Peer-Vergleich
Kursveränderung
Heron Therapeutics Inc Prognose
Stimmung
By Acuity
18 / 340 Ranking in Gesundheitswesen
Nachrichtenstimmung
Sehr starke bullische Evidenz
Volatilität
Unterdurchschnittlich
Nachrichtenvolumen (RCV)
Überdurchschnittlich
Finanzen
Vertriebs- und Verwaltungskosten
Betriebsaufwand
Gewinn vor Steuern
Verkäufe
Umsatzkosten
Bruttogewinn aus dem Verkauf
Zinsaufwand für Schulden
EBITDA
Betriebsergebnis
$
Über Heron Therapeutics Inc
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.